Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria

Brahm H. Segal, Raoul Herbrecht, David A. Stevens, Luis Ostrosky-Zeichner, Jack Sobel, Claudio Viscoli, Thomas J. Walsh, Johan Maertens, Thomas F. Patterson, John R. Perfect, Bertrand Dupont, John R. Wingard, Thierry Calandra, Carol A. Kauffman, John R. Graybill, Lindsey R. Baden, Peter G. Pappas, John E. Bennett, Dimitrios P. Kontoyiannis, Catherine CordonnierMaria Anna Viviani, Jacques Bille, Nikolaos G. Almyroudis, L. Joseph Wheat, Wolfgang Graninger, Eric J. Bow, Steven M. Holland, Bart Jan Kullberg, William E. Dismukes, Ben E. De Pauw

Research output: Contribution to journalReview articlepeer-review

280 Scopus citations

Abstract

Invasive fungal diseases (IFDs) have become major causes of morbidity and mortality among highly immunocompromised patients. Authoritative consensus criteria to diagnose IFD have been useful in establishing eligibility criteria for antifungal trials. There is an important need for generation of consensus definitions of outcomes of IFD that will form a standard for evaluating treatment success and failure in clinical trials. Therefore, an expert international panel consisting of the Mycoses Study Group and the European Organization for Research and Treatment of Cancer was convened to propose guidelines for assessing treatment responses in clinical trials of IFDs and for defining study outcomes. Major fungal diseases that are discussed include invasive disease due to Candida species, Aspergillus species and other molds, Cryptococcus neoformans, Histoplasma capsulatum, and Coccidioides immitis. We also discuss potential pitfalls in assessing outcome, such as conflicting clinical, radiological, and/or mycological data and gaps in knowledge.

Original languageEnglish (US)
Pages (from-to)674-683
Number of pages10
JournalClinical Infectious Diseases
Volume47
Issue number5
DOIs
StatePublished - Sep 1 2008

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria'. Together they form a unique fingerprint.

Cite this